{"id":1140,"date":"2024-08-02T14:24:02","date_gmt":"2024-08-02T06:24:02","guid":{"rendered":"https:\/\/flcube.com\/?p=1140"},"modified":"2024-10-14T11:17:59","modified_gmt":"2024-10-14T03:17:59","slug":"kyowa-kirin-revamps-apac-strategy-exits-china-and-shifts-rd-focus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1140","title":{"rendered":"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus"},"content":{"rendered":"\n

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151<\/a>) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only a select few core global brands. This strategic shift also extends to Kyowa Kirin\u2019s research and development (R&D), with a pivot from small-molecule research to antibodies and hematopoietic stem cell gene therapy (HSC-GT).<\/p>\n\n\n\n

China Operations to Winhealth<\/strong><\/p>\n\n\n\n

Kyowa Kirin will close down its China operations, transferring its portfolio, including five established brands, to a special-purpose company. The equity will then be transferred to Hong Kong-based Winhealth Pharma Group Co., Ltd for a deal valued at RMB 720 million (approximately USD 100 million). Alongside this, commercial rights for Kyowa Kirin’s global products Crysvita (burosumab) and Poteligeo (mogamulizumab) in China will also be handed to WinHealth.<\/p>\n\n\n\n

APAC Rights to DKSH<\/strong><\/p>\n\n\n\n

Kyowa Kirin is also transferring commercial rights for its established products in Hong Kong\/Macau, South Korea, Malaysia, Singapore, Taiwan, and Thailand to DKSH Holding Ltd. The specifics of the DKSH license deal remain undisclosed, marking a significant divestment of Kyowa Kirin\u2019s APAC operations.<\/p>\n\n\n\n

R&D Overhaul<\/strong><\/p>\n\n\n\n

In a separate announcement, Kyowa Kirin revealed plans to concentrate its R&D on bone and mineral, hematologic cancers\/intractable hematologic diseases, and rare diseases, focusing on advanced antibody technologies and HSC-GTs. The company will phase out in-house small molecule drug discovery research activities, along with related manufacturing and CMC research and quality-related activities, initiating a voluntary retirement program for affected employees.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[438,1212],"class_list":["post-1140","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-kyowa-kirin","tag-tyo-4151"],"yoast_head":"\nKyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan's pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only a select few core global brands. This strategic shift also extends to Kyowa Kirin\u2019s research and development (R&D), with a pivot from small-molecule research to antibodies and hematopoietic stem cell gene therapy (HSC-GT).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1140\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1140\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-02T06:24:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T03:17:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1140#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1140\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus\",\"datePublished\":\"2024-08-02T06:24:02+00:00\",\"dateModified\":\"2024-10-14T03:17:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1140\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Kyowa Kirin\",\"TYO: 4151\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1140#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1140\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1140\",\"name\":\"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-02T06:24:02+00:00\",\"dateModified\":\"2024-10-14T03:17:59+00:00\",\"description\":\"Japan's pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only a select few core global brands. This strategic shift also extends to Kyowa Kirin\u2019s research and development (R&D), with a pivot from small-molecule research to antibodies and hematopoietic stem cell gene therapy (HSC-GT).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1140#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1140\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1140#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus - Insight, China's Pharmaceutical Industry","description":"Japan's pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only a select few core global brands. This strategic shift also extends to Kyowa Kirin\u2019s research and development (R&D), with a pivot from small-molecule research to antibodies and hematopoietic stem cell gene therapy (HSC-GT).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1140","og_locale":"en_US","og_type":"article","og_title":"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1140","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-02T06:24:02+00:00","article_modified_time":"2024-10-14T03:17:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1140#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1140"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus","datePublished":"2024-08-02T06:24:02+00:00","dateModified":"2024-10-14T03:17:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1140"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Kyowa Kirin","TYO: 4151"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1140#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1140","url":"https:\/\/flcube.com\/?p=1140","name":"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-02T06:24:02+00:00","dateModified":"2024-10-14T03:17:59+00:00","description":"Japan's pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only a select few core global brands. This strategic shift also extends to Kyowa Kirin\u2019s research and development (R&D), with a pivot from small-molecule research to antibodies and hematopoietic stem cell gene therapy (HSC-GT).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1140#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1140"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1140#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1140"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1140\/revisions"}],"predecessor-version":[{"id":6391,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1140\/revisions\/6391"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}